Acute Exacerbation of CRS Treatment Market: Introduction
According to the report, the global acute exacerbation of CRS treatment market was valued over US$ 4.33 Bn in 2020. It is projected to expand at a CAGR of 4.6% from 2021 to 2031. Rhinosinusitis is a major health issue globally. It is an infection of the nasal passages and paranasal sinuses. It has three cardinal symptoms: nasal obstruction, purulent nasal discharge, and facial pain-pressure-fullness. Nasal obstruction is defined by the patient as obstruction, congestion, blockage, or stuffiness; purulent nasal discharge is cloudy or colored in appearance; and facial pain-pressure-fullness involves the anterior face and periorbital region or manifests with headache that can be localized or diffuse.
The rise in cases of rhinosinusitis is expected to drive the acute exacerbation of CRS treatment market during the forecast period. According to the CDC, approximately 28.9 million adults were diagnosed with rhinosinusitis in the U.S. in 2018. Additionally, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the global acute exacerbation of CRS treatment market.
Acute Exacerbation of CRS Treatment Market Segmentation
In terms of treatment, the global acute exacerbation of CRS treatment market has been segregated into treatment, route of administration, distribution channel, and infection type. Treatment consists of antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others. The route of administration segment consists of topical, nasal, oral, and injectable. In terms of distribution channel, the global acute exacerbation of CRS treatment market has been split into online pharmacies, retail pharmacies, and hospital pharmacies. Based on infection type, the global acute exacerbation of CRS treatment market has been categorized into staphylococcus species and others.
In terms of treatment, the global acute exacerbation of CRS treatment market has been segmented into antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others. The antibiotics segment dominance is attributed to the high prescription of antibiotics in acute exacerbation of CRS by physicians.
Acute Exacerbation of CRS Treatment Market Drivers
During the projected period, the acute exacerbation of CRS treatment market is anticipated to be driven by an increase in instances of rhinosinusitis. For instance, The prevalence of chronic rhinosinusitis (CRS) worldwide ranges from about 8% in China, 8.4% in Korea, 11% in Europe, and 12% in the U.S. As a result, the worldwide Acute Exacerbation of CRS Treatment market is expected to grow as the number of instances of chronic rhinosinusitis rises.
Regional Segmentation of Acute Exacerbation of CRS Treatment Market
North America dominated the global acute exacerbation of CRS treatment market in 2020, and the trend is anticipated to continue during the forecast period. The U.S. is anticipated to dominate the market in North America during the forecast period, owing to the presence of a large number of key players, high healthcare expenditure, and reimbursement policies favoring the usage of acute exacerbation of CRS treatment in the country.
Surge in healthcare expenditure and rise in awareness about sinusitis are anticipated to fuel the market in Asia Pacific. The market in Asia Pacific is also projected to expand due to robust healthcare expenditure on R&D of pharmaceutical drugs.
The market in Europe is anticipated to be driven by an increase in the demand for drugs for the treatment of acute exacerbation of CRS. Additionally, increase in awareness regarding acute exacerbation of CRS and focus on discovering novel treatment drugs are anticipated to fuel the market in the region.
The study also presents profiles of leading players in the global market for acute exacerbation of CRS treatment. These include Sun Pharmaceutical Industries, Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Abbott Laboratories, Bayer AG, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Amneal Pharmaceuticals LLC, GlaxoSmithKline plc., Aurobindo Pharma, Hikma Pharmaceuticals plc, Wockhardt, and Mylan N.V.
Leading companies in the global market for acute exacerbation of CRS treatment are focused on strengthening the distribution chain and expansion of the product range to gain market share. For instance, on July 26 2020, Novartis announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Xolair (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP), for whom therapy with INC does not provide adequate disease control. If approved, omalizumab would be the first treatment for nasal polyps, specifically targeting and blocking immunoglobulin E (IgE), which helps to reduce the size of nasal polyps (as defined by Nasal Polyps Score; NPS) and improve symptoms.
Global Acute Exacerbation of CRS Treatment Market: Segmentation
- Acute Exacerbation of CRS Treatment Market, by Treatment
- Leukotriene Inhibitors
- Nasal Saline Irrigation
- Oral Corticosteroids
- Endoscopic sinus surgery
- Acute Exacerbation of CRS Treatment Market, by Route of Administration
- Acute Exacerbation of CRS Treatment Market, by Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Acute Exacerbation of CRS Treatment Market, by Infection Type
- Staphylococcus Species
- Acute Exacerbation of CRS Treatment Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- North America
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC